Novo Nordisk, which recently agreed to acquire three Catalent fill-finish sites, has announced plans to invest $4.1 billion to build a second fill and finishing manufacturing facility in Clayton, North Carolina, and grow its ability to produce current and future injectable treatments for people with obesity and other serious chronic diseases.   The expansion will add 1.4 million square feet of production space for aseptic manufacturing and finished production processes, doubling the combined...